ASTA Medica subsidiary Muro hopes to establish a marketing partner by early June to promote Optivar to ophthalmologists and eye care specialists following FDA approval May 22 for "treatment of itching of the eye associated with allergic conjunctivitis." An internal sales force, which Muro is growing to 200 reps, will market the product to allergists, respiratory specialists and general practitioners. An early fall product launch is anticipated
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth